SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Targeted Therapies in NSCLC

Targeted Therapies in NSCLC

Targeted Therapies in NSCLC Current Standards and Challenges in ALK+ and EGFR+ NSCLC Oliver Gautschi Unlocking Synergies with Chemo, Bispecifics and TKIs Jarushka Naidoo LATEST ADVANCES IN RECURRENT EGFR+ NSCLC: FOCUS ON MET Nicolas Girard  10 JULY 2025 } 1 h 30 min...
Immunotherapies in NSCLC

Immunotherapies in NSCLC

IO in early stage & combinations in late NSCLC LESS IS MORE – NEOADJUVANT IO ALONE IS UNDOUBTEDLY SUFFICIENT Patrick Forde EMBRACING ADDITIONAL ADJUVANT IO: A CRUCIAL AND NECESSARY ADD-ON Jordi Remon MAXIMIZING OUTCOMES: THE ROLE OF IO COMBINATIONS Solange Peters...
Small Cell Lung Cancer

Small Cell Lung Cancer

Small Cell Lung Cancer THE EMERGING ROLE OF DLL3 T-CELL ENGAGERS IN SCLC Giannis Mountzios EXPANDING OUR OPTIONS WITH IO COMBINATION THERAPIES IN LS- AND ES-SCLC Jacob Sands Open Discussion, Viewer Questions & Patient Cases Solange Peters  17 June 2025 } 1 h 35...

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates